G. Tezel et al., Clinical factors associated with progression of glaucomatous optic disc damage in treated patients, ARCH OPHTH, 119(6), 2001, pp. 813-818
Background: Reducing intraocular pressure (IOP) in glaucomatous eyes does n
ot always prevent disease progression.
Objective: To determine the clinical factors associated with progressive op
tic disc damage in glaucomatous eyes receiving treatment to reduce IOP.
Methods: Baseline and follow-up optic disc photographs as well, as demograp
hic and clinical data were retrospectively studied in 186 eyes of 93 patien
ts with primary open-angle glaucoma, and in 138 eyes of 69 patients with no
rmal-pressure glaucoma. The patients with primary open-angle glaucoma were
included in the study only if their treated IOPs during a follow-up period
of 5 years were less than 21 mm Hg. The patients with normal-pressure glauc
oma were included only if their IOPs were reduced by at least 20% during th
e follow-up period, The association of progressive optic disc damage with p
atient- and eye-specific characteristics was examined using multivariate an
alysis.
Results: During the 5-year study period, 141 (43.5%) of the 324 eyes exhibi
ted progressive optic disc damage defined by at least a 5% decrease in the
neural rim area-to-disc area ratio. Using multivariate analysis, the follow
ing were found to be strongly associated with progressive neural rim damage
: a baseline smaller neural rim area-disc area ratio (P < .001); a baseline
larger zone P area-disc area ratio (P=.04); a baseline larger parapapillar
y atrophy length-disc circumference ratio (P=.05); a diagnosis of normal-pr
essure glaucoma (P=.01); and combined medical and surgical treatment prior
to the study period (P=.01).
Conclusions: Clinical factors other than IOP may be important indicators of
subsequent progression of glaucomatous optic disc damage. Our findings sug
gest that eyes with advanced glaucomatous optic disc damage and normal-pres
sure glaucoma are more likely to progress despite receiving treatment to re
duce IOP.